Close Menu

NEW YORK (GenomeWeb) – University of Maryland startup Biomecite Diagnostics has exclusively optioned the rights from UM Baltimore to develop molecular diagnostics to detect inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

The deal between Biomecite and University of Maryland Ventures covers technology developed by Florian Fricke and James White at the University of Maryland School of Medicine's Institute for Genome Sciences. The technology links distinctive genomic variants in the human gut microbiome to the two related, but unique forms of IBD.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.